US20060211013A1

US20060211013A1 - Method for sorting antifungal molecules acting on the glucanosyltransferase activity

Info

Publication number: US20060211013A1
Application number: US11/326,609
Authority: US
Inventors: Thierry Fontaine; Robbert Hartland; Isabelle Mouyna; Jean-Paul Latge
Original assignee: Individual
Current assignee: Individual
Priority date: 1996-08-30
Filing date: 2006-01-06
Publication date: 2006-09-21
Also published as: US5989895A; AU4121997A; WO1998008937A1; EP0932665B1; US20030152986A1; ES2312178T3; DE69738945D1; JP2001501814A; EP0932665A1; US20030147856A1; US7060454B2; US7022495B2; ATE406437T1; US6551811B1

Abstract

The invention discloses proteins having β(1-3)glucanosyltransferase type activities. These proteins can be used for detecting the antifungal activity of molecules.

Description

This is a division of application Ser. No. 10/347,252, filed Jan. 21, 2003, which is a division of application Ser. No. 09/242,913, filed Oct. 13, 1999, now U.S. Pat. No. 6,551,811, which is a Section 371 application of PCT/FR97/01540, filed Aug. 29, 1997, and further claims the benefit of U.S. Provisional Application No. 60/024,910, filed Aug. 30, 1996, the disclosures of all of which are incorporated herein by reference.
This invention relates to a protein with an activity of the glucanosyltransferase type, and more especially a β-(1-3)-glucanosyltransferase activity.
This invention also relates to oligonucleotides coding for this protein having an enzymatic activity.
It also relates to molecules having an effect on the activity of this enzyme.
Opportunistic fungal infections due to Candida, Aspergillus, Cryptococcus and Pneumocystis are responsible for the increase in morbidity and mortality among patients suffering from AIDS and other patients with clinically compromised immunity. In addition, the yeast Candida and the dermatophytes today remain a major medical problem amongst patients with adequate immunity. Despite the increase in the number of infections due to pathogenic and opportunistic fungi, therapy against mycoses has not improved in recent years. Two families of drugs are used: the azoles and Amphotericin B. These drugs have some disadvantages since treatment based on Amphotericin B is associated with nephrotoxicity and that based on azole is more fungistatic than fungicidal.
Fungi are microorganisms of the eukaryotic type which share the majority of their biochemical pathways with their hosts, with one important exception: the biosynthesis of the cell wall. The cell wall is a rigid envelope which protects the cell against the environment and mechanical stresses, but is also a dynamic structure which is involved in the transport of ions and macromolecules and in the localization of enzymes involved in fungal growth. In consequence, disorganization of the organization of the cell wall should be detrimental to fungi.
The skeleton of the fungal cell wall is mainly composed of polymers of the polysaccharide type (β(1-3) glucans, mannans, chitin) which are not found in humans. For this reason, the biosynthesis of the cell wall has been a target for research into new antifungal drugs. The penicillins and cephalosporins, which are both inhibitors of the bacterial cell wall, and potential antibiotics lend support to this hypothesis. Moreover, many molecules which inhibit the development of the fungal cell wall have antifungal properties (Debono and Gordee, 1994, Annu. Rev. Microbiol, 48, 471-497). Among these are:

- 1) The families of the echinocandin lipopeptides and the palulacandin glycopeptides which are non-competitive inhibitors of the glucan synthetase complex.
- 2) The polyoxins and nikkomycins which are analogs of UDP-GlcNac and potential competitive inhibitors of chitin synthetase, and
- 3) The pradimycins binding mannan and the benanomycins.

The synthesis of β(1-3) glucan and chitin is under the control of enzyme complexes (glucan synthetase and chitin synthetase) which are localized in the plasma membrane. Once the polymers have been released into the periplasmic space, cross-links are created between the polymers and it is these which are responsible for the rigidity of the cell wall. The proteins and genes of the glucan and chitin synthetases are beginning to be fairly well understood.
However, the inhibition of the glucan and chitin synthetases by a molecule requires three steps: its transfer across the cell wall, crossing of the plasma membrane and transfer inside the cell to the target, each step representing a potential barrier for the enzymatic inhibitor from being an effective antifungal drug or a potential source of resistant strains against the drug.
The transferases which are responsible for creating the covalent bonds between the different polymers of the wall have been very little studied up till now.
These enzymes represent a better target than the chitin and glucan synthetase complexes since they are more easily accessible for a putative antifungal drug.
Nuoffer et al. (1991, Mol. Cell. Bio., 11, 27-37) have described a glycoprotein, named Gas1p, exposed on the surface of the yeast Saccharomyces cerevisiae. The genes coding for this protein have been cloned. The function of the Gaslp protein is not essential for the viability of the cell, and has not been determined.
Saporito-Irwing et al. (1995, Mol. Cell. Biol., 15, 601-613) have isolated a gene originating from the yeast Candida albicans, designated PHR1. The amino acid sequence determined for this protein PHR1 was 56% identical to that of the protein Gas1. The gene was regulated in response to the pH of the culture medium. As for the protein gas1p, no function has been determined.
It clearly emerges from this analysis of the prior art that there has been a problem in obtaining molecules with effective antifungal activity.
The inventors have solved this problem.
They have shown that the introduction of mutations into a glucanosyltransferase originating from Aspergillus fumigatus interferes with the development of this microorganism.
They have also determined the sequences of several of these enzymes.

The present invention thus relates to a first protein with an activity of the β(1-3)-glucanosyltransferase type characterized in that it has at least 50%, preferably 60%, and even more preferably 85% homology with proteins having the sequences, or a part of the sequences SEQ ID NO. 2 or SEQ ID NO. 3 as follows:


	SEQ ID NO:2:
	Met Lys Ala Ser Ala Val Thr Ala Ala Leu Ala Val
	Gly Ala Ser Thr Val Leu Ala Ala Pro Ser Ile Lys
	Ala Arg Asp Asp Val Thr Pro Ile Thr Val Lys Gly
	Asn Ala Phe Phe Lys Gly Asp Glu Arg Phe Tyr Ile
	Arg Gly Vai Asp Tyr Gln Pro Gly Gly Ser Ser Asp
	Leu Ala Asp Pro Ile Ala Asp Ala Asp Gly Cys Lys
	Arg Asp Ile Ala Lys Phe Lys Glu Leu Gly Leu Asn
	Thr Ile Arg Val Tyr Ser Val Asp Asn Ser Lys Asn
	His Asp Glu Cys Met Asn Thr Leu Ala Asp Ala Gly
	Ile Tyr Leu Val Leu Asp Val Asp Thr Pro Lys Tyr
	Ser Ile Asn Arg Ala Lys Pro Lys Glu Ser Tyr Asn
	Asp Val Tyr Leu Gln Tyr Ile Phe Ala Thr Val Asp
	Ala Phe Ala Gly Tyr Lys Asn Thr Leu Ala Phe Phe
	Ser Gly Asn Glu Val Ile Asn Asp Gly Pro Ser Ser
	Ser Ala Ala Pro Tyr Val Lys Ala Val Thr Arg Asp
	Leu Arg Gln Tyr Ile Arg Ser Arg Lys Tyr Arg Glu
	Ile Pro Val Gly Tyr Ser Ala Ala Asp Ile Asp Thr
	Asn Arg Leu Gln Met Ala Gln Tyr Met Asn Cys Gly
	Ser Asp Asp Glu Arg Ser Asp Phe Phe Ala Phe Asn
	Asp Tyr Ser Trp Cys Asp Pro Ser Ser Phe Lys Thr
	Ser Gly Trp Asp Gln Lys Val Lys Asn Phe Thr Gly
	Tyr Gly Leu Pro Leu Phe Leu Ser Glu Tyr Gly Cys
	Asn Thr Asn Lys Arg Gln Phe Gln Glu Val Ser Ser
	Leu Tyr Ser Thr Asp Met Thr Gly Val Tyr Ser Gly
	Gly Leu Val Tyr Glu Tyr Ser Gln Glu Ala Ser Asn
	Tyr Gly Leu Val Glu Ile Ser Gly Asn Asn Val Lys
	Glu Leu Pro Asp Phe Asp Ala Leu Lys Thr Ala Phe
	Glu Lys Thr Ser Asn Pro Ser Gly Asp Gly Asn Tyr
	Asn Lys Thr Gly Gly Ala Asn Pro Cys Pro Ala Lys
	Asp Ala Pro Asn Trp Asp Val Asp Asn Asp Ala Leu
	Pro Ala Ile Pro Glu Pro Ala Lys Lys Tyr Met Thr
	Glu Gly Ala Gly Lys Gly Pro Gly Phe Ala Gly Pro
	Gly Ser Gln Asp Arg Gly Thr Gln Ser Thr Ala Thr
	Ala Glu Pro Gly Ser Gly Ser Ala Thr Gly Ser Ser
	Ser Ser Gly Thr Ser Thr Ser Ser Lys Gly Ala Ala
	Ala Gly Leu Thr Val Pro Ser Leu Thr Met Ala Pro
	Val Val Val Gly Ala Val Thr Leu Leu Ser Thr Val
	Phe Gly Ala Gly Leu Val Leu Leu


	SEQ ID NO: 3: (BGT2)
	Asp Asp Val Thr Pro Ile
	Thr Val Lys Gly Asn Ala Phe Phe Lys Gly Asp Glu
	Arg Phe Tyr Ile Arg Gly Val Asp Tyr Gln Pro Gly
	Gly Ser Ser Asp Leu Ala Asp Pro Ile Ala Asp Ala
	Asp Gly Cys Lys Arg Asp Ile Ala Lys Phe Lys Glu
	Leu Gly Leu Asn Thr Ile Arg Val Tyr Ser Val Asp
	Asn Ser Lys Asn His Asp Glu Cys Met Asn Thr Leu
	Ala Asp Ala Gly Ile Tyr Leu Val Leu Asp Val Asn
	Thr Pro Lys Tyr Ser Ile Asn Arg Ala Lys Pro Lys
	Glu Ser Tyr Asn Asp Val Tyr Leu Gln Tyr Ile Phe
	Ala Thr Val Asp Ala Phe Ala Gly Tyr Lys Asn Thr
	Leu Ala Phe Phe Ser Gly Asn Glu Val Ile Asn Asp
	Gly Pro Ser Ser Ser Ala Ala Pro Tyr Val Lys Ala
	Val Thr Arg Asp Leu Arg Gln Tyr Ile Arg Ser Arg
	Lys Tyr Arg Glu Ile Pro Val Gly Tyr Ser Ala Ala
	Asp Ile Asp Thr Asn Arg Leu Gln Met Ala Gln Tyr
	Met Asn Cys Gly Ser Asp Asp Glu Arg Ser Asp Phe
	Phe Ala Phe Asn Asp Tyr Ser Trp Cys Asp Pro Ser
	Ser Phe Lys Thr Ser Gly Trp Asp Gln Lys Val Lys
	Asn Phe Thr Gly Tyr Gly Leu Pro Leu Phe Leu Ser
	Glu Tyr Gly Cys Asn Thr Asn Lys Arg Gln Phe Gln
	Glu Val Ser Ser Leu Tyr Ser Thr Asp Met Thr Gly
	Val Tyr Ser Gly Gly Leu Val Tyr Glu Tyr Ser Gln
	Glu Ala Ser Asn Tyr Gly Leu Val Glu Ile Ser Gly
	Asn Asn Val Lys Glu Leu Pro Asp Phe Asp Ala Leu
	Lys Thr Ala Phe Glu Lys Thr Ser Asn Pro Ser Gly
	Asp Gly Asn Tyr Asn Lys Thr Gly Gly Ala Asn Pro
	Cys Pro Ala Lys Asp Ala Pro Asn Trp Asp Val Asp
	Asn Asp Ala Leu Pro Ala Ile Pro Glu Pro Ala Lys
	Lys Tyr Met Thr Glu Gly Ala Gly Lys Gly Pro Gly
	Phe Ala Gly Pro Gly Ser Gln Asp Arg Gly Thr Gln
	Ser Thr Ala Thr Ala Glu Pro Gly Ser Gly Ser Ala
	Thr Gly Ser Ser Ser Ser Gly Thr Ser Thr Ser Ser
	Lys Gly Ala Ala Ala Gly Leu Thr Val Pro Ser Leu
	Thr Met Ala Pro Val Val Val Gly Ala Val Thr Leu
	Leu Ser Thr Val Phe Gly Ala Gly

This protein preferably has a molecular weight of about 44 kD, or of about 49 kD if it carries at least one residue of the N-glycosyl type.
The present invention also relates to proteins with β-(1-3)-glucanosyltransferase activity characterized in that they have at least 50%, preferably 60% and even more preferably 85% homology with proteins having the sequences, or a part of the sequences SEQ ID NO. 10 or SEQ ID NO. 12 as follows:

SEQ ID NO 10:

Gly Phe Phe Ala Gly Asn Glu Val Ile Asn Glu Gln

Ser Val Lys Asn Val Pro Thr Tyr Val Arg Val Cys

His Pro Ser Pro Gln Leu Thr Ile Ala Cys Pro Leu


	SEQ ID NO 12 (BGT4)
	Gly Phe Phe Ala Gly Asn Glu Val Val Asn Gln Ala
	Asn Gln Ser Ala Gly Ala Ala Phe Val Lys Ala Ala
	Ala Arg Asp Met Lys Ala Tyr Ile Lys Thr Lys Gly
	Tyr Arg Gln Ser Leu Ala Ile Gly Tyr Ala Thr Thr
	Asp Asn Pro Glu Ile Arg Leu Pro Leu Ser Asp Tyr
	Leu Asn Cys Gly Asp Gln Ala Asp Ala Val Asp Phe
	Phe Gly Tyr Asn Ile Tyr Glu Trp Cys Gly Asp Gln
	Thr Phe Gln Thr Ser Gly Tyr Gln Asn Arg Thr Glu
	Glu Tyr Lys Asp Tyr Ser Ile Pro Ile Phe Ile Ser
	Glu Tyr Gly Cys Asn

The present invention also relates to fragments of these proteins.
Said invention is not limited to the proteins having the sequences SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 10 or SEQ ID NO. 12 but extends to any protein having sequences similar to those having the sequences SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 10 or SEQ ID NO. 12 and in particular having certain amino acid substitutions in which an amino acid is replaced by another amino acid having essentially the same physico-chemical properties. Lehninger's biochemistry manual (Flammarion Medecine-Science, 1977, or one of its more recent editions) distinguishes four groups of amino acids, based on their physico-chemical behavior: those with a non-polar or hydrophobic side-chain, those with an uncharged polar side-chain, those with a negatively charged side-chain, and those with a positively charged side-chain.
The present invention also relates to nucleotide sequences coding for proteins, or protein fragments such as those described above, and more particularly DNA sequences (cDNA or genomic DNA) or RNA sequences.

Such a DNA sequence may be that having at least 50%, preferably 60% and even more preferably 85% homology with the genomic sequence SEQ ID NO. 1, or a part of the sequence SEQ ID NO. 1 as follows:


	ATG AAG GCC TCT GCT GTT ACT GCC GCT CTC GCC GTC
	GGT GCT TCC ACC GTT CTG GCA GCC CCC TCC ATC AAG
	GCT CGT GAC GAC GTT ACT CCC ATC ACT GTC AAG GGC
	AAT GCC TTC TTC AAG GGC GAT GAG CGT TTC TAT ATT
	CGC GGT GTC GAC TAC CAG CCC GGT GGC TCC TCC GAC
	CTG GCT GAT CCC ATC GCT GAT GCC GAT GGT TGC AAG
	CGT GAC ATT GCC AAG TTC AAG GAG CTG GGC CTG AAC
	ACT ATC CGT GTC TAC TCG GTC GAC AAC TCC AAG AAC
	CAC GAT GAG TGT ATG AAT ACA CTG GCT GAT GCT GGC
	ATC TAT CTG GTG CTC GAT GTC AAC ACT CCC AAG TAC
	TCC ATC AAC CGC GCC AAG CCT AAG GAG TCG TAC AAC
	GAT GTC TAC CTC CAG TAT ATC TTC GCT ACC GTT GAT
	GCT TTC GCC GGT TAC AAG AAC ACC CTC GCT TTC TTC
	TCC GGC AAC GAG GTT ATC AAC GAT GGC CCT TCC TCC
	TCT GCT GCT CCC TAC GTC AAG GCC GTC ACT CGT GAT
	CTG CGT CAG TAC ATC CGT AGC CGC AAG TAC CGT GAG
	ATT CCT GTC GGC TAC TCG GCT GCC GAT ATC GAC ACC
	AAC CGT CTT CAG ATG GCC CAG TAT ATG AAC TGC GGT
	TCC GAC GAC GAG CGC AGT GAC TTC TTC GCT TTC AAC
	GAC TAC TCC TGG TGC GAT CCC TCC TCT TTC AAA ACC
	TCG GGC TGG GAT CAG AAG GTC AAG AAC TTC ACT GGC
	TAC GGT CIT CCT CTC TTC CTG TCC GAA TAC GGC TGC
	AAC ACC AAC AAG CGT CAA TTC CAA GAA GTC AGC TCT
	CTC TAC TCC ACG GAC ATG ACT GGT GTC TAC TCF GGT
	GGT CTC GTG TAC GAG TAC TCT CAG GAG GCC AGC AAC
	TAC GGT CTG GTG GAG ATT AGC GGC AAC AAT GTC AAG
	GAG CTC CCA GAC TTC GAC GCT CTG AAG ACC GCG TTC
	GAA AAG ACC TCC AAC CCC TCC GGC GAC GGC AAC TAC
	AAC AAG ACT GGT GGT GCC AAC CCT TGC CCC GCT AAG
	GAC GCT CCC AAC TGG GAC GTT GAC AAC GAT GCT CTT
	CCT GCC ATC CCC GAG CCC GCC AAG AAG TAC ATG ACT
	GAG GGT GCT GGC AAG GGC CCT GGT TTT GCC GGA CCT
	GGC AGC GAG GAC CGT GGT ACC GAG TCC ACT GCC ACT
	GCT GAG CCC GGA TCT GGC TCT GCC ACT GGA AGC AGC
	AGC AGC GGC ACC TCC ACC TCT TCC AAG GGC GCT GCA
	GCT GGC CTG ACT GTC CCT AGC CTG ACC ATG GTC CCC
	GTT GTC GTT GGT GCG GTT ACA CTC CTG TCC ACC GTC
	TTC GGC GCT GGC CTC GTC CTC TTG TGA

This sequence has been included in a 2.2 kb fragment, which has itself been included in the X bal site of the pUC19 vector (Maniatis et al., 1989, Cold Spring Harbor Laboratories Press). The strain E. coli DH₅α carrying this modified vector was deposited in the Collection Nationale de Culture de Micro-Organismes at the Institut Pasteur (CNCM) on the 26 Jul. 1996 under the number I-1763.
Such a sequence may also be that having at least 50%, preferably 60% and even more preferably 85% homology with the complementary DNA sequence comprised in a 1.4 kb fragment, which has been included in the pCRII vector (In Vitrogen). This, carried by the E. coli DH₅α strain, was deposited in the Collection Nationale de Culture de Micro-Organismes at the Institut Pasteur (CNCM) on the 26 Jul. 1996 under the number I-1762.
These two strains are objects of the present invention.

Nucleotide sequences according to the present invention may also be those having at least 50%, preferably 60%, and even more preferably 85% homology with one of the DNA sequences SEQ ID NO. 9 or SEQ ID NO. 11 as follows:


	SEQ ID N0 9:
	GGCTTCTTCG CCGGCAACGA GGTTATCAAC GAGCAGAGTG
	TCAAGAACGT TCCCACTTAC GTCCGGGTAT GTCATCCATC
	CCCACAGCTT ACGATTGCCT GTCCACTGAC ACTCTCGTAG
	GCGACTCAGC GTGACATGAA GGACTACTAC GCAAAGAACC
	TTGACCGCAG CATTCCTGTT GGCTATTCTG CTGCCGATAT
	TCGTCCCATC CTCATGGCAC CCCTCAACTA CTTCATGTGC
	GCTGAGGATG CTAATTCCCA ATCGGACTTC TTCGGCCTCA
	ACTCCTACTC GTGGTGCGGC AACTCGTCCT ACACCAAGAG
	TGGCTACGAT GTCCTCACCA AGGACTTTGC CGACGCCTCT
	ATCCCCGTCT TCATCTCCGA ATTCGGCTGC AACA


	SEQ ID NO 11
	GGTTTCTTCG CCGGCAACGA GGTTGTGAAT CAGGCGAATC
	AGTCCGCCGG CGCTGCATTC GTCAAGGCCG CCGCGCGAGA
	CATGAAGGCC TACATCAAGA CCAAGGGATA CCGGCAATCG
	CTGGCAATTG GATACGCGAC CACTGACAAC CCGGAAATCC
	GACTCCCGCT GTCCGACTAC CTCAACTGCG GCGACCAGGC
	CGACGCGGTC GACTTCTTCG GCTACAACAT CTACGAATGG
	TGCGGTGACA AGACCTTCCA GACCTCGGGC TACCAGAACC
	GCACCGAGGA GTACAAGGAC TACTCCATCC CCATCTTCAT
	CTCCGAATAC GGCTGCAAC

These two sequences have been independently included in the pCRII vectors and introduced into the E. coli DH5α strain. These strains were deposited in the Collection Nationale de Culture de Micro-Organismes at the Institut Pasteur (CNCM) on the 22 Aug. 1997 under the numbers I-1914 and I-1913.
A further object of the present invention is a method for the detection of proteins with a strong homology with the sequence of the protein BGT2.
The present invention thus relates to a method for detecting a nucleotide sequence having at least 60% identity with the sequence SEQ ID NO. 1 in a biological sample containing nucleotide sequences, comprising the following steps:
a) placing the biological sample in contact with the nucleotide primers P3 and P4 having the sequences SEQ ID NO. 7 and SEQ ID NO. 8, respectively, as follows:

SEQ ID NO 7:

GSYTTCTTCK CYGGCAACGA GGTT


	SEQ ID NO 8:
	GTTGCAGCCG WATTCGGASA YGAA

the nucleotide sequences contained in the sample having been if necessary put into a form enabling their hybridization under conditions enabling the hybridization of the primers with the nucleotide sequences.

- b) amplification of the nucleotide sequences
- c) revealing the amplification products, and
- d) detection of the mutations by appropriate methods.

The proteins according to the invention may be obtained by purification of an autolysate of Aspergillus fumigatus. The protein may be purified by four steps of ion-exchange chromatography and one step of gel filtration.
Said proteins may also be obtained by genetic engineering methods. For example, the sequence SEQ ID NO. 1, if possible without its C-terminal part, may be cloned in an appropriate vector, and expressed in an expression system, such as the Pichia pastoris system, marketed by In Vitrogen.
In this system, the sequence of the gene coding for the protein is cloned in an expression vector, then linearized. Protoplasts originating from P. pastoris are transformed with the linearized vector.
The clones, in which a recombination is performed and which replaces the aox1 sequence by the sequence of the gene of the protein which it is desired to produce, are selected for their capacity to grow in a histidine-deficient medium. A person skilled in the art may refer to “Manual of methods for expression of recombinant proteins in Pichia pastoris”, published by In Vitrogen.
The protein thus expressed, if possible secreted in the culture medium, is recovered by processes known to a person skilled in the art.
Such a protein may be used, in particular, for screening molecules to identify their antifungal activity.
Thus, another object of the present invention is a process for screening molecules to identify their antifungal activity comprising the following steps:

- placing together the molecules to be screened and the protein or the protein fragment as described above, or coded by a sequence such as described above, and
- determining the effect of the molecule on said protein.

The determination of the effect of the molecules on said protein may be accomplished by measuring the activity of the β-(1-3) glucanosyltransferase (BGT2). Such activity may be determined by placing said protein in the presence of a substrate on which it has an effect, which may be composed of laminarioligosaccharides comprising at least 10 glucosyl radicals linked by β-(1-3) bonds. When the protein is active, it cleaves a part of the molecule and binds the fragment obtained onto the non-reducing terminal of an uncleaved substrate molecule.
The product resulting from the activity of the protein is in the form of coupling products of two laminarioligosaccharides. This product may be detected by any process allowing the separation of oligosaccharides with different degrees of polymerization, in particular by chromatographic methods, such as high-pressure liquid chromatography, (HPLC) or thin-layer chromatography (TLC). Ths latter method, although less precise than the first, is the easier to use.
For the use of these chromatographic methods, a person skilled in the art may consult the following manual: Carbohydrate analysis:a practical approach. Chaplin and Kennedy, 1986 IRC Press, Oxford.
This detection method enables determination as to whether the molecules detected have antifungal activity.
These molecules having antifungal activity show effects on the β-(1-3)glucanosyltransferase activity of said proteins. These effects may be for example the inhibition of this activity.
The present invention also relates to molecules having an effect on said proteins, which may be detected by the process as described above, as well as the use of these molecules to prepare a drug, or for the treatment of diseases related to fungi, in vertebrates and plants.
One of the advantages of the use of these molecules lies in the low frequency of appearance of resistant strains of the fungi, in contrast to other known antifungal molecules.
The present invention is illustrated, without being limited, by the following examples:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an analysis of the SDS-PAGE type of the purified 49 kDa protein: line a, molecular weight standards; line b, purified 49 kDa protein (1.5 μg); line c, purified 49 kDa protein (1.5 μg) after treatment with N-glycosidase F; line d, N-glycosidase alone. The molecular weights of the protein bands and N-glycosidase F are shown.
FIG. 2 represents an HPAEC-type analysis of the products arising from the incubation of the 49 kDa enzyme with the reduced laminarioligosaccharides. The purified 49 kDa protein was incubated with 8 mM of reduced laminarioligosaccharides of size G₁₁, G₁₂, G₁₃or G₁₄(reduced laminarioligosaccharides with 11, 12, 13 or 14 glucose residues respectively) and the HPAEC profiles arising from these samples are shown at time zero and 15 min, with the sizes of the main products.
FIG. 3 represents an HPAEC-type analysis of the products arising from the incubation of the 49 kDa enzyme with 8 mM of rG₁₆. The HPAEC profiles arising from these samples are shown at time zero, 30 min and 120 min, with the sizes of the main products.
FIG. 4 illustrates the action of the transferase and the products formed from the reduced laminarioligosaccharides.
FIG. 5 shows the effect of varying concentrations of the substrates. The 49 kDa transferase was incubated with 3 μM of [³H]-rG₁₁(1×10⁶cpm) plus varying quantities of unmarked rG₁₁. The % of transfer was determined by comparing the proportion of marking formed in the form of rG₆and rG₁₆. The inset shows the same data with the concentration of the substrates presented in the form of a linear scale.
FIG. 6 illustrates the effect of pH on the transfer rate. The 49 kDa transferase was incubated with 8 μM of [³H]-rG₁₁(1×10⁶cpm). The reaction rates were determined by measuring the quantity of marking formed in the form of the product rG₁₆. The buffers used were: ●, sodium citrate/citric acid; ∘, imidazole/citric acid; x, sodium acetate/acetic acid; ▪, Tris/glycine; ▴, phosphate/NaOH; ˜, Tris/acetic acid; Δ, glycine/HCl.
FIG. 7 shows the sequence originating from the gene BGT2 from A. fumigatus (A) compared with genes PHR1 and GAS1 isolated from C. albicans (C) and S. cerevisiae (S). The underlined amino acid sequence corresponds to the presumed intron.
FIG. 8 shows the growth rate of mutant 49 compared to that of the wild strain. Where a pH value is stated, the culture was performed at controlled pH (4 or 7).
FIG. 9 illustrates the growth of the wild strain and that of the mutant Δ49 and the variation of the pH of the culture medium during the growth of the two strains.
FIGS. 10A-10 c are comparisions of the sequences of the protein with sequence SEQ ID NO. 2 and the five following proteins: Phr 1p, Gas 2p, Gas 3p, Gas 4p and Gas 5p.
FIGS. 11 and 12 are restriction maps of the sequences of the genes homologous with the BGT2 gene, named BGT4 and BGT3 respectively.

EXAMPLES

Experimental Procedures
1. Preparation of the Cell Wall and Autolysis.
The strain CBS 144-89 of type A. fumigatus (available from the Collection Centralbureau voor Schimmelculture) was grown in a 15 L fermenter in 2% glucose, 1% mycopeptone (Biokar Diagnostics) plus 0.1% silicone antifungal 426R (Rhodorsil) at 25° C. (agitation at 500 r.p.m., aeration 0.5 vol.vol⁻¹. min⁻¹. for 42 h). A culture which had grown for 3 days in a 2 L fermenter under the same conditions was used as the inoculum (8%(v/v)). The mycelia were collected by filtration under vacuum and ruptured by passing through a Dyno type mixer in the presence of glass beads (W. A. Bachofen A G, Basel, Switzerland) (0.5-0.75 mm diameter). The progression of the disruption of the cells was monitored microscopically. The suspension of the ruptured mycelia was centrifuged (8000 g, 15 min) and the residue containing the cell walls was washed 3 times with water and once with 50 mM Na acetate, pH 5.6 containing 5 mM Na azide, then resuspended in the same buffer (250 g wet weight per L of buffer) and incubated (agitation 200 r.p.m.) at 37° C. After 72 h, the suspension was centrifuged (10000 g, 15 min) and the supernatant was placed in a dialysis tube, concentrated 5 to 10 times with polyethylene glycol 20000, dialyzed against 5 mM Na acetate, pH 5.6, recentrifuged (10000 g, 15 min) and filtered (0.45 μm filter). This preparation is subsequently referred to as the autolysate.
2. Enzyme Purification
The fractions collected during each step of the chromatography were tested for enzymatic activity using the non-radioactive transferase test (see below). The dialyzed and concentrated autolysate was applied to a 4×18 cm DEAE-SEPHAROSE FAST-FLOW column (Pharmacia) equilibrated with 5 mM Na acetate, pH 5.6, and the column was eluted with a linear gradient up to 1M NaCl (2000 ml) at a flow rate of 240 ml.h⁻¹. The fractions containing transferase activity were collected, dialyzed against a buffer containing 10 mM β-mercaptoethanol, 5 mM EDTA, 10 mM Na acetate, pH 4.0, applied to a MONO S column (HR 5/5 Pharmacia), and eluted with a linear gradient of NaCl (0 to 300 mM in 40 min) at a flow rate of 0.8 ml.min⁻¹. The fraction containing transferase activity was collected, dialyzed against 10 mM Tris/HCl, pH 7.0, and applied to a DEAE-5PW column (8×75 mm, TosoHaas), and eluted with a linear gradient up to NaCl (0 to 300 mM in 60 min) with a flow rate of 0.75 ml.min⁻¹. The fractions containing transferase activity were collected, dialyzed against a buffer containing 10 mM β-mercaptoethanol, 5 mM EDTA 10 mM EDTA, 10 mM Na acetate, pH 4.0, and applied to a CM-5PW column (8×75 mm, TosoHaas), and eluted with a linear gradient of NaCl (0 to 300 mM in 60 min) with a flow rate of 0.8 ml.min⁻¹. The fractions containing transferase activity were collected and concentrated by a speed-vac and fractionated on a SUPERDEX HR75 column (Pharmacia) equilibrated with 10 mM Tris/HCl, pH 7.0 containing 150 mM NaCl, at a flow rate of 0.75 ml.min⁻¹. The fractions containing purified transferase were collected, dialyzed against 5 mM Na citrate, pH 5.0, concentrated by speed-vac and stored at −20° C. until used.
3. Transferase Assays
The enzyme fractions were assayed for transferase activity by incubation in 50 mM Na citrate, pH 5.0 at 37° C. (10 μl volume per assay) with a laminarioligosaccharide reduced with borohydride (8 mM final) of at least size G₁₀. Samples (3 μl) were taken at different times, 50 mM NaOH cooled in ice (47 μl) was added to terminate the reaction, and the mixture was frozen until analyzed by high-performance anion-exchange chromatography (HPAEC). Since the peak intensities detected by Pulsed Electrochemical Detector (PED) varied from day to day, the transferase activity was quantified by use of reduced laminarioligosaccharides marked with ³H as substrates and measurement of the appearance of the marking in the products after separation by HPAEC chromatography, using the on-line Radiomatic 150TR scintillation rate analysis apparatus (Packard). Except where otherwise mentioned, the assays for the enzyme characterization studies were performed as above with 0.25 μg of purified transferase.
4. Colorimetric Determinations
The β-glucanase activity was measured in the protein fractions by a sugar reduction test using the reagent hydroxybenzoic acid hydrazide with laminarin reduced by borohydride instead of carboxymethyl pachyman as substrate (Ram et al., 1988, Life Sci Adv., 7, 379-383). The exo-β-glucanase/β-glucosidase activities were measured by incubating the enzyme fractions with p-nitrophenyl-β-D-glucopyranoside (Hartland et al., 1991, Proc. R. Soc. London B, 246, 155-160). The quantity of the proteins was estimated using the Biorad protein test according to the manufacturer's instructions, with bovine serum albumin as standard.
5. High-Performance Anion-Exchange Chromatography
The samples from the transferase tests were analyzed on a Dionex CARBOPAC PA1 analytical column (4×250 mm) (with a PA1 reference column) on a Dionex HPAEC-type system with pulsed electrochemical detection (PED-2 cell), fitted with a combination of pH-Ag/AgCl reference electrodes and using a potential of 0.4 V for the first 0.5 s of detection. The oligosaccharides were eluted under the following conditions: flow rate 1 ml/min, buffer A: 50 mM NaOH; buffer B: 500 mM sodium acetate in 50 mM NaOH; gradient 0 to 2 min, 98% A 2% B (isocratic), 2 to 15 min 75% A 25% B (linear), 15 to 45 min 60% A 40% B (linear). The laminarioligosaccharide standards were obtained from Seikagaku (Japan).
6. Thin-Layer Chromatography (TLC)
The laminarioligosaccharides were revealed by thin-layer chromatography on silica gel 60 (Kieselgel, Merck) using n-butanol/acetic acid/water (2/1/1.5) as eluant and sulfuric orcinol coloration. The degree of polymerization (dp) of the oligosaccharides was also determined by HPAE-type chromatography using a pulsed electrochemical detector and an anion-exchange column (CARBO6PAC PA1, 4.6×250 mm, Dionex).
7. Preparation of Reduced Substrates
The laminarioligosaccharides were obtained by partial acid hydrolysis (6.5 M TFA, 15 min, 100° C., followed by 1 M TFA, 45 min, 100° C.) of curdlan (Serva). The TFA was removed by rotary evaporation in the presence of methanol. The oligosaccharides were reduced overnight with NaBH₄(1:0.5 (w/w) in 0.1 M NaOH at room temperature). The reduced ends of the laminarioligosaccharides marked with ³H were similarly prepared by reduction with NaB³H₄(Amersham, 20-40 Ci/mmol, 10 mCi per mg of oligosaccharide) overnight followed by a subsequent reduction by NaBH₄as before. The excess of NaBH₄, was destroyed by addition of acetic acid up to pH 5-6, and the borate salts were removed by rotary evaporation in the presence of methanol. The reduced oligosaccharides were desalted by gel filtration on a SEPHADEX G15 column (1.2×80 cm, 8 ml.h¹⁻, equilibrated in water) and collected after detection by the orcinol-sulfuric acid method (Ashwell, 1966, Methods Enzymol, 8, 85-95). The laminarioligosaccharides were separated by HPAEC on a CARBOPAC PA1 preparative column (9×250 mm, Dionex) with a Na acetate gradient 15 to 350 mM in 50 mM NaOH (45 min) at a flow rate of 4 ml.min⁻¹. The oligosaccharide fractions collected were neutralized with acetic acid, desalted by gel filtration on a SEPHADEX G15 column as described above, then lyophilized. The laminarin (Sigma) was reduced in the same way, but desalted by dialysis against 0.5% acetic acid, followed by dialysis against water, then lyophilized. The gentiooligosaccharides were prepared as above (without reduction) from pulsatin (Calbiochem) which had been finely divided with a pestle and mortar. The maltoheptaose and cellopentaose were from Boehringer Mannheim and Sigma, respectively. The chitohexaose was a gift from Dr. A Domard (Université Claude Bernard, Villeurbanne, France). G₁₀reduced with borohydride containing a β-(1-6) intrachain bond at the sixth link from the reduced end (rG₁₀*) was obtained by incubating the reduced laminarihexose (rG₆) with an enzyme homologous with the BGT1 enzyme from Candida purified from A. fumigatus. The product from the transferase rG₁₀* was separated and purified as for the laminarioligosaccharides above.
7. Electrophoresis on SDS-Polyacrylamide Gel
The protein samples were analyzed by SDS-PAGE (Laemmli, 1970, Nature, 227, 680-685) using 10% separation gels and 4% stacked gels. The protein bands were revealed by coloration with Coomassie blue. The N-glycosylation of the glycoproteins was performed using the recombinant N-glucosidase F (Oxford GlycoSystems) according to the manufacturer's instructions.
8. ¹H NMR Spectroscopy
Two samples were analyzed: the reduced laminarioligosaccharide G₁₀used as standard and a reduced oligosaccharide G₁₆obtained after incubation of rG₁₀with the transferase and purified by HPAEC. The deuterium in the samples dried by lyophilization was replaced by dissolution in D₂O (99.95%, Solvents Documentation Synthese, France). The spectra were recorded at 300 K and 318 K on Variant Unity 500 spectrometer operating at a proton frequency of 500 MHz. The OH resonance of the residual water was removed by selective radiation during the relaxation time. Sodium 3-trimethylsilylpropionic acid was used as external standard.

Example 1

Purification of the 49 kDa Protein

A high-performance anion-exchange chromatography (HPAEC) test using laminarioligosaccharides reduced with borohydride as substrates was developed to study the activities of the β-glucanosyl transferase associated with the cell wall of A. fumigatus. A new β-(1-3)-glucosyl transferase activity was detected in the semi-purified fractions from the autolysate of the cell wall of A. fumigatus, which remained associated with a 49 kDa protein throughout its purification.
The protein was purified to apparent homogeneity with four steps of ion-exchange chromatography and one gel filtration step.
The activity of the transferase was clearly detectable after only the second chromatography step (MONO S). The analysis by SDS-PAGE of the purified fraction showed a main band at 49 kDa (FIG. 1, well b). In order to determine if it contained an N-linked carbohydrate, the protein was digested with N-glucosidase F. The digested protein passed on SDS-PAGE as 44 kDa protein, (FIG. 1, well c) showing that it contained about 5 kDa of N-linked carbohydrate.

Example 2

Enzymatic Activity of the 49 kDa Protein

HPAEC analysis of the products resulting from the incubation of the 49 kDa protein with a laminarioligosaccharide reduced with borohydride (rG_n) of size G₁₀or larger led to the characterization of a new activity of glucanosyl transferase type.
The principal initial products arising from the incubation with rG₁₁were rG₆and rG₁₆; rG₁₂gave rG₆+rG₇and rG₁₇+rG₁₈, rG₁₃gave rG₆to rG₈and rG₁₈to rG₂₀, and rG₁₄gave rG₆to rG₉and rG₁₉to rG₂₂(FIG. 2). Significantly, no products of the laminarioligosaccharide type, reduced or not, were detected, confirming the absence of any endo-β-(1-3)-glucanase activity. The presence of such activity would have caused the formation of a mixture of hydrolysis products, reduced or not, the latter having different retention times. In addition, no glucose was detected, and together with the absence of hydrolysis of p-nitrophenyl-β-glucopyranoside and the formation in the network of reducing sugar arising from the laminarin reduced with borohydride in the corresponding colorimetric tests, this confirmed the absence of exo-β-(1-3)-glucanase and β-glucosidase activity.
The profile of the products obtained (FIG. 2) is in agreement with an endogenous type of glucanosyl transferase activity in which the glucan chain is cleaved by an endolytic cleavage, freeing the portion of the reduced end, and the remainder is transferred to another glucan chain, to form a larger transferase product. Thus, in the simplest reaction with rG₁₁, the enzyme cleaves the substrate, liberating rG₆from the reduced end of the substrate molecule, and the remaining G₅is then transferred to another rG₁₁molecule acting as receptor, to form a transferase-type product rG₁₆:
E+rG₁₁→E.G₅+rG₆
E.G₅+rG₁₁→E+rG₁₆
where E represents the enzyme. The transferase cleaves rG₁₂in two different places, leading to two different transferase-type products:
E+rG₁₂→E.G₆+rG₆
→E.G₅+rG₇
E.G₆+rG₁₂→E+rG₁₈
E.G₅+rG₁₂→E+rG₁₇
Similarly with rG₁₃and rG₁₄, the transferase cleaves in three or four different places, respectively, each time transferring the part of the non-reduced end to another acceptor molecule rG₁₃or rG₁₄.
Additional analyses of incubations of the 49 kDa transferase with reduced or smaller laminarioligosaccharides showed that the reaction with rG₁₀gave rG₅+rG₆and rG₁₄+rG₁₅, as initial major products, while the reaction with rG₉was extremely slow, forming small peaks of rG₅to rG₈and rG₁₀to rG₁₃. No products were detected after incubation with laminarioligosaccharides of size G₈or smaller.
In order to determine the relative reaction rate of the enzymes with laminarioligosaccharides of variable sizes, the 49 kDa enzyme (0.25 μg) was incubated with 8 mM of rG₁₀to rG₁₅marked with ³H and the rate of formation of the marked products was measured. The rate with rG₁₀(328 nmol.min⁻¹) was approximately equal to 50% of that with the larger substrates and there was no significant difference between the reaction rates for rG₁₁to rG₁₅(648±46 nmol.min⁻¹.mg protein⁻¹).
Analysis of longer incubations of the purified enzymes with reduced laminarioligosaccharides of size at least G₁₀showed that the products from the initial transferase could be re-used either as donors or as acceptors, leading to the formation of products of increasing size, until they are eliminated from the solution because of their insolubility in the aqueous buffer. An incubation of 30 min with rG₁₆(containing some contaminating rG₁₅) led to the formation of reduced initial major products of sizes G₆to G₁₁and G₂₁to G₂₆(FIG. 3), but after 120 min, larger transferase products appeared with sizes of at least G₄₀(FIG. 3). The products with sizes G₂₉and larger precipitated at the bottom of the incubation tube since they were absent when the reaction mixture was briefly centrifuged and the supernatant analyzed. Incubation of the purified enzyme with reduced laminarin led to the production of smaller and larger products, showing that soluble oligosaccharides of size at least G₃₀and larger can act as donors and acceptors in the reaction.
In order to determine the smallest laminarioligosaccharide which could act as acceptor, the purified transferase was incubated with 4 mM of rG₁₁as donor and 16 mM of rG₈or smaller as acceptor. Analyses of the incubations of rG₁₁rG₄or smaller showed the formation of rG₆and rG₁₆as the only initial major products, showing that only rG₁₁had been used as acceptor. However, incubations containing rG₁₁and rG₅to rG₈showed additional transferase products consistent with the use of the latter oligosaccharides as acceptors. For example, the reaction of rG₁₁and rG₇led to the initial formation of rG₆, rG₁₂and rG₁₆consistent with:
E+rG₁₁→E.G₅+rG₆
E.G₅+rG₁₁→E+rG₁₆
E.G₅+rG₇→E+rG₁₂
The relative rate of the reaction with the acceptors was determined by using 2 mM of rG₁₁as donor and 32 mM of reduced acceptor marked with ³H and measuring the formation of marked transferase product (FIG. 4). Under these conditions, the reaction with rG₁₁used as acceptor was negligible. The reaction rate increased with an increase in chain length, showing that the 49 kDa enzyme prefers the larger laminarioligosaccharide acceptors.
The transferase showed no activity towards the gentiooligosaccharides (size G_3-8), chitohexaose, cellopentaose or maltoheptaose, either in the presence or absence of rG₁₁, suggesting that the enzyme exclusively uses a β-(1-3) glucan as donor. This was demonstrated by using a reduced branched G₁₀(rG₁₀*) similar to the laminaridecaose, except that the sixth link from the reduced end is a β-(1-6)-type link. Incubation of the 49 kDa enzyme with 8 mM of rG10* gave no products, showing that it was not a donor. However, a similar incubation in the presence of 2 mM of rG₁₁led to the formation of rG₆and an elution peak in the position of rG₁₅as initial major products, showing that rG₁₀* can act as an acceptor.

Example 3

¹H NMR Analysis of the Reduced G₁₆Transferase Product

In order to determine if the 49 kDa transferase had produced a new type of bond during the transfer, the product rG₁₆of the transferase was purified from the incubation medium of the transferase with rG₁₁. Approximately 300 μg of the product were analyzed by ¹H NMR. The 1D spectrum of the product rG₁₆of the transferase showed three chemical shifts in the anomeric region:
δ=4.68 ppm corresponding to the glucose residue linked to the glucitol group;
δ=4.75 ppm corresponding to the glucose residue of the non-reduced end;
δ=4.80 ppm corresponding to the intrachain residues of glucose, linked β-(1-3).
The relative intensities of the anomeric signals showed 1, 1 and 13 protons respectively. Since the glucitol gives no signals in the anomeric region, this confirms the length of the oligosaccharide (16 residues), The coupling constants measured for these signals were in agreement with β-linked glucose residues (³J_1,2=7.9 Hz). The presence of a single unit of the glucose type at the non-reduced end indicates that the 49 kDa protein had been transferred to the non-reduced end of the β-(1-3) glucan acceptor.
The 1D spectrum of the product rG₁₆was identical, except for the relative intensity of the 4.80 ppm signal compared to that of the rG₁₀laminarioligosaccharide standard. In addition, no chemical shift characteristic of a glucose residue linked (1-2), (1-4) or (1-6) was visible, confirming that the rG₁₆product was a laminari-hexadecaose. The conjoint elution of the rG₁₆product with the rG₁₆reference on HPAEC and the insolubility of the larger product are in agreement with the production of a β-(1-3)-type bond during the transfer.

Example 4

Effect of Substrate Concentration on the Reaction Products

In order to determine whether the concentration decreasing of acceptors stimulated the hydrolysis reactions, the 49 kDa transferase was incubated with 3 μl of [³H]-rG₁₁and decreasing quantities of unmarked rG₁₁. A shift from the transfer (i) to the hydrolysis (ii) was observed (FIG. 5, inset):
E+[³H]-rG₁₁→E.G₅+[³H]-rG₆
(i)→E.G₅+[³H]-rG₁₁→E+[³H]-rG₁₆
(ii)→E.G₅+H₂O→E+G₅
The percentage of transfer was determined by measuring the formation of marked rG₁₆(transfer only) compared with that of marked rG₆(transfer plus hydrolysis) in the reaction. At an rG₁₁concentration of 3 mM, only transfer was detected. As the substrate concentration reduced to 18 μM, the percentage of transfer leveled out at about 35% and did not decrease significantly with a low substrate concentration (3 μM) (FIG. 5). Reduction of the buffer concentration to 10 mM did not change the transfer percentage for any substrate concentration. It seems that below the given conditions, the 49 kDa transferase was unable to catalyze more than about 65% of hydrolysis by simply reducing the substrate concentration to very low levels.

Example 5

Optimum pH and Stability

The 49 kDa enzyme was tested at different pH values, the storage stability was verified and the activity of the N-glycosylated enzyme was tested. The enzyme was active over a wide range of acid pH, showing an activity of more than 50% of its maximum between pH 2.5 and 6.0. The enzyme showed a pH optimum of about 5.0 in citrate buffer (FIG. 6). The enzyme was very stable and could be stored at 4° C. in 10 mM citrate buffer, pH 5.0 for several weeks, or dried by a speed-vac and then re-suspended in a buffer, or stored at −20° C. without significant loss of activity. The 44 kDa de-N-glycosylated enzyme prepared under non-denaturing conditions was as active as the native glycosylated enzyme when incubated with 8 mM of rG₁₁.

Example 6

Kinetic Analysis

The 49 kDa enzyme catalyzed its transferase-type reaction by a bi-reaction type mechanism (two steps) with an initial hydrolysis of the substrate to liberate the portion of the reduced end, and a subsequent transfer of the remainder of the non-reduced end to a substrate molecule playing the role of an acceptor molecule.
By using rG₁₁as substrate, it was impossible to calculate an apparent Km corresponding to the two steps of the reaction. In order to determine a Km for the donor site, we used an acceptor which was not a donor. We used [³H]-rG₇(1×10⁶cpm) as acceptor at a high concentration (64 mM) with different concentrations of rG₁₁kept below 8 mM. Under these conditions, the reaction took place with rG₁₁as donor and rG₇was used rather than rG₁₁as acceptor, as determined by the absence of formation of the transferase product rG₁₆. The initial reaction rate was determined by measuring the appearance of marked rG₁₂.
An apparent Km of 5.3 mM was obtained from reciprocal double spots (value of r²=0.997).

Example 7

Cloning, Sequencing and Interruption of the Gene Coding for BGT2 in A. fumigatus

Two amino acid sequences were obtained from the purified BGT2 protein. The NH₂terminal sequence was DVTPITVKGNAFFKGDERFY (SEQ ID NO: 20) and an internal sequence was DAPNWDVDNDALP (SEQ ID NO: 21). An oligonucleotide of 38 units on the N-terminal part having the following sequence SEQ ID NO: 4:

(AAA GG(T/C) AA(C/T) GC(T/C) TTC TT(C/T) AAG GG(T/C) GA(T/C) GAG CG(T/C) TTC TA)
was used to screen a gene bank created in the phage EMBL3 after partial digestion by Sau3A of the DNA of A. fumigatus as described by Monod (1994, 33-40, Mol. Biology of pathogenic fungi, B. Maresca and G. S. Kobayashi).

The transfer was performed on membranes of the ZETAPROBE type. The membranes were pre-hybridized and hybridized at 50° C. in a solution containing SSC 5×, Na₂HPO₄20 mM, pH7, SDS 7%, Denhard 10× and 1% salmon sperm. The membranes were washed twice at 42° C. in a solution containing SSC 3×, Denhard 10×, SDS 5%, Na₂HPO₄25 mM, and twice in an SDS solution with 1% SSC 1×.
The cloning and sequencing of the gene coding for the BGT2 protein showed significant homologies with the genes PHR1 and GAS1 previously identified in C. albicans and S. cerevisiae respectively (Saporito Irwin and Coll. (1995) Mol. Cell Biol., 15, 601-613; Nuoffer and Coll., J. Biol. Chem., (1991), 226, 19, 12242-12248) (FIG. 7). The GAS 1 gene from S. cerevisiae was also responsible for a glucanosyl transferase activity. In this fungus species, the minimum size of optimal substrate was G10, rather than G11 for A. fumigatus.
The disruption of the BGT2 gene was carried out by using the vector pAN7-1 (Punt and Coll. (1987) Gene 56, 117-124) supplied by P. Punt (TNO, Rijinsik). This vector was modified as pN4 (Paris and Coll. (1993) FEMS Microbiol. Lett. 111, 31-36) by the replacement of a restriction site HindIII by a Smal site. About 50% of the open reading frame of BGT2 was replaced by pN4 at an EcoRV restriction site. A complete transformation was performed as previously described (Paris, (1994) Isolation of protease negative mutants of Aspergillus fumigatus by insertion of a disrupted gene, p. 49-55. Mol. Biology of pathogenic fungi, B. Maresca and G. S. Kobayashi) by using protoplasts produced by Novozyme and the linearized plasmid in the presence of PEG.
The Δ49 mutant from A. fumigatus obtained was deposited on 30 Jul. 1996 at the CNCM under the deposit number I-1764.
It showed no phenotype distinct from the wild strain, except for a total inhibition of the growth in the fermenter after 24 hours growth.

Example 8

Cloning and Sequencing of the cDNA of BGT2

The cDNA of BGT2 was obtained by amplification with two primers of cDNA type 5′ GAATTCGACGACGTTACTCCCATCACT 3′ (SEQ ID NO: 5) of P1 and 5′ TCTAGAGGGTATGAGAAGAACAAATCA 3′ (SEQ ID NO: 6) of P2 obtained from 10 ng of cDNA, 1 U of taq polymerase, 200 mM of each primer. 30 Amplification cycles were performed, comprising 1 minute at 95° C., one minute at 55° C. and one minute at 72° C.
The amplified preparation was then cloned in a vector using a TA Cloning kit (In Vitrogen).

Example 9

Expression of the (β-(1-3)-glucanosyltransferase

Experiments using Triton X114 divisions with or without treatment with GPI-, phospholipase C showed that the protein BGT2 from A. fumigatus was attached to the plasma membrane by a GPI residue.
The attachment of the protein to the membrane was not necessary for retention of enzymatic activity. We showed that in A. fumigatus the same activity was present when the protein was either free in the culture medium (in the absence of the GPI bond) or attached to the plasma membrane.
These results suggested that the expression of the glucanosyltransferase could be performed in vectors by a secreted expression. The Pichia pastoris expression system from In Vitrogen was selected. This system bad been previously used for another 88 kDA protein from A. fumigatus and it was confirmed that Pichia preserved the glycosylation site of the native protein very well.
The vector used was pPICZα (In Vitrogen) for the secretion with a myc epitope and six histidine residues in tandem for easy purification. The C-terminal sequence responsible for the attachment by GPI was removed before the sub-cloning in pPICZα so as to obtain an enzymatically active truncated secreted protein.
This recombinant protein was used for the detection of antifungal drugs. The inhibition of the enzymatic activity may be measured by an HPLC-type detection in the absence of cleavage and an additional elongation of any β-(1-3) laminarioligosaccharides with dp>10 in the presence of p49 from A. fumigatus.
The absence of motility of the laminarioligosaccharide measured by thin-layer chromatography by conventional techniques or directly after marking of the reduced end with a chromogenic or fluorogenic radical could be a fundamental technique for performing detection automatically.
Since the product from the β-(1-3) glucanosyltransferase becomes insoluble in an aqueous medium, because of the elongation of the β-glucan chain, the absence of precipitation of any product after prolonged incubation using a radioactively marked substrate could also be used for drug detection.

Example 10

Identification of Genes with Homologies with BGT2

Degenerate oligonucleotide primers corresponding to the regions retained in the sequence in FIG. 10 were synthesized by GENSET. They had the following sequences:
SEQ ID NO. 7 (P3): 5′GSYTTCTTCKCYGGCAACGAGGTT 3′
SEQ ID NO. 8 (P4′): 5′GTTGCAGCCGWATTCGGASAYGAA 3′ in which Y is C or T
K is T or G
S is C or G
W is A or T.
PCR reactions were carried out in a volume of 100 μl containing 1.5 mM MgCl2, 50 mM Kcl, 10 mM TrisCl (pH 8), 250 μM of dATP, dGTP, dCTP and dTTP (Pharmacia), 1 μM of each primer, 2.5 units of AMPLITAQ DNA polymerase (Pharmacia) and 50 ng of genomic DNA. The amplification was performed in an OmniGene apparatus initially for 5 min at 93° C., then for 30 cycles of 1 min at 93° C., then for 1 min at 50° C. and 1 min at 72° C. The products from the PCR reaction were analyzed by electrophoresis on 1% agarose gel, then revealed by ultraviolet after coloration with ethidium bromide.
The fragments resulting from the PCR reaction were ligatured in pCR2.1 (TA cloning kit, In Vitrogen). The recombinant plasmid inserts were sequenced by the dideoxy chain termination method (Sanger et al., 1977) using SEQUENASE, Version 2 (US Biochemicals) according to the manufacturer's instructions.
Two nucleotide sequences were thus amplified: sequences SEQ ID NO. 9 and SEQ ID NO. 11. The amino acid sequences deduced from the nucleotide sequences were sequences SEQ ID NO. 10 and SEQ ID NO. 12, corresponding to the genes named BGT4 and BGT3.
These sequences are in particular described in the list below. They have identity percentages with BGT2 of 41% and 37% respectively.
Restriction maps of the two sequences SEQ ID NO. 10 and SEQ ID NO. 12 are represented respectively in FIGS. 12 and 11.
The sequences SEQ ID NO. 9 and SEQ ID NO. 11 were inserted into the plasmid PCRII which was introduced into E. coli. These bacteria were deposited on the 22 Aug. 1997 at the CNCM under numbers I-1914 and I-1913 respectively.

TABLE

Reaction of the transferase with an initial rate of formation of the transfer product Transferase reaction Transfer rate (nmol.min⁻¹.mg proteins⁻¹) rG₁₁+[³H]−rG₅- →RG₆+[³H]rG₁₀203 rG₁₁+[³H]−rG₆→RG₆+[³H]−rG₁₁387 rG₁₁+[³H]-rG₇→RG₆+[³H]-rG₁₂484 rG₁₁+[³H]−rG₈→RG6+[³H]−rG_{13 586}

Claims

1-23. (canceled)

24. An isolated protein having β-(1-3)-glycanosyltransferase type activity, wherein the protein has at least 50% homology with a protein comprising SEQ ID NO 2.

25. The protein according to claim 24, wherein the protein comprises at least one site for N-linked glycosylation.

26. The protein according to claim 24, wherein the protein is attached to a plasma membrane by a glycosylphosphatidylinositol radical.

27. The protein according to claim 24, wherein said protein has at least 60% homology with a protein comprising SEQ ID NO 2.

28. The protein according to claim 24, wherein said protein has at least 85% homology with a protein comprising SEQ ID NO 2.

29. A polypeptide fragment having β-(1-3)-glycanosyltransferase type activity of the protein according to any one of claims 24-28.